Table 4. Incidence of complications after 70- and 120-w ThuVEP with mechanical morcellation, as well as previously reported incidences after HoLEP, OP and TURP, given as a percentage and/or range.
| 70-w ThuVEPn (%) | 120-w ThuVEPn (%) | Total ThuVEPbn (%) | HoLEPe(%) | OPe(%) | TURPe(%) | |
|---|---|---|---|---|---|---|
| No. of patients | 44 | 40 | 84 | |||
| Early complications | ||||||
| Death/myocardial infarction/pulmonary embolisma | — | — | — | |||
| Intraoperative blood transfusions | — | — | — | |||
| Postoperative blood transfusions | — | 1 (2.5) | 1 (1.2) | 0–1.93, 4, 5, 16, 17, 18, 19, 20, 23, 24, 25 | 1–322, 16, 26, 27, 29, 30 | 0–221, 17, 18, 19, 20, 28 |
| TURS | — | — | — | — | — | 0–51, 17, 18, 19, 20, 28 |
| Transient irritative urinary symptoms | 8 (18.2) | 9 (22.5) | 17 (20.2) | 0–4416, 17, 18, 19, 20, 25 | 7.46–38.6016, 26 | 0–38.617, 18, 19, 20 |
| Transient stress incontinence | 2 (4.5) | 1 (2.5) | 3 (3.6) | 0–7.15, 16, 20, 22, 25 | 2.50–5.9716, 26, 27, 29, 30 | 0–401, 17, 18, 19, 20 |
| Recatheterisation | 1 (2.3) | 2 (5) | 3 (3.6) | 0.4–17.05, 16, 19, 20, 25 | 3.3–5.116, 29 | 0–13.31, 17, 18, 19, 20 |
| Haemorrhage requiring coagulation | 1 (2.3) | 1 (2.5) | 2c (2.4) | 0–616, 17, 18, 19, 20, 25 | 1.1–3.726, 27, 29 | 0–14.31, 17, 18, 20 |
| Residual adenoma at the apex of prostate fossa | 1 (2.3) | 1 (2.5) | 2 (2.4) | 0–3.316, 17, 18, 20 | 0–1.126, 27, 29, 30 | 0–3.318, 20 |
| Clot retention | 1 (2.3) | 1 (2.5) | 2 (2.4) | 0–3.620, 23, 24, 25 | 0–11.616, 26, 27, f 29 | 0–3920 |
| Incomplete morcellation | — | 2 (5) | 2d (2.4) | 0–3.723, 25 | — | — |
| Overall immediate re-operation rate | 2 (4.5) | 4 (10) | 6 (7.2) | 0–55, 16, 17, 18, 20, 23, 24 | 0.5–3.726, 27, 29, 30 | 2.2–5.61, 17, 18, 28 |
| Complications at 12-month follow-up | ||||||
| Cumulative rate of UTI | 4 (9.1) | 4 (10) | 8 (9.52) | 0–65, 19, 20, 22, 24, 25 | 5.1–12.9 26, 27/g8.629 | 0–251, 19, 20, 28 |
| Epididymitis | — | 2 (5) | 2 (2.4) | 0.6–0.722, 25 | 430 | h0–41 |
| Persistent irritative urinary symptoms | 3 (6.8) | 1 (2.5) | 4 (4.76) | 0–10.816, 17, 20, 25 | 0–8.516, 26, 29 | 0–3.317, 19 |
| Persistent urge/stress incontinence | — | — | — | 0–5.416, 17/0–3.35, 16, 17, 18, 19, 20, 24 | 0–8.52, 16, 26, 29, 30/0–202, 16, 26, 27, 29 | 0–3.31, 17, 18, 19/0–2.21, 17, 18, 19, 20 |
| Bladder neck contracture/urethral stricture | 1(2.3) | 1(2.5) | 2(2.4) | 1.4–6.43, 4, 16, 17, 18 | 3.3–5.73, 16, 29 | 2.2–7.417, 18 |
Abbreviations: HoLEP, holmium laser enucleation of the prostate; OP, open prostatectomy;ThuVEP, Tm:YAG VapoEnucleation of the prostate; TURP, transurethral resection of the prostate; TURS, transurethral resection syndrome; UTI, urinary tract infection; —, none.
a
Within the first 30 days postoperatively.
b
No statistical differences between 70- and 120-w ThuVEP.
c
Re-operation due to haemorrhage with clot retention.
d
Procedure abandoned and completed 48 h later.
e
For clarity, n is not shown, as the studies cited included pooled results from meta-analyses.
f
Information given as severe bleeding.
g
Sepsis.
h
Epididymitis/urinary tract infection.